Cargando…
VAD chemotherapy as remission induction for multiple myeloma.
A total of 142 patients with multiple myeloma received VAD as remission induction therapy. Seventy-five were previously untreated and 67 had relapsed (31) or refractory disease (36). Vincristine (total dose 1.6 mg) was infused with doxorubicin 36 mg m-2 by continuous ambulatory pump over 4 days. In...
Autores principales: | Anderson, H., Scarffe, J. H., Ranson, M., Young, R., Wieringa, G. S., Morgenstern, G. R., Fitzsimmons, L., Ryder, D. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1995
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033610/ https://www.ncbi.nlm.nih.gov/pubmed/7841049 |
Ejemplares similares
-
VAD Chemotherapy versus Bortezomib Containing Regimens as Remission Induction For ASCT in Multiple Myeloma: A Single Center Experience
por: Yıkılmaz, Aysun Şentürk, et al.
Publicado: (2020) -
Is there a role for ‘modified VAD’ in the treatment of multiple myeloma?
por: Agazzi, A, et al.
Publicado: (2009) -
The VAD Scheme versus Thalidomide plus VAD for Reduction of Vascular Endothelial Growth Factor in Multiple Myeloma: A Meta-Analysis
por: He, Gan-Lin, et al.
Publicado: (2018) -
Oral acyclovir prophylaxis against herpes simplex virus in non-Hodgkin lymphoma and acute lymphoblastic leukaemia patients receiving remission induction chemotherapy. A randomised double blind, placebo controlled trial.
por: Anderson, H., et al.
Publicado: (1984) -
(333) Transitioning Vad Care: Outcomes of Virtual Vad Follow Up Visits
por: Meehan, K., et al.
Publicado: (2023)